A drug compound that is directed towards RUNX1 is Ibrutinib, which affects signaling of the B cell antigen receptor (BCR) in the case of Non-Hodgkin Lymphoma [30]. This evidence concerns the gene BCR and non-Hodgkin lymphoma.